SBI Securities’s NeuroSense Therapeutics NRSN Stock Holding History

SBI Securities’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.84K	Buy	640 +627	+4,823%	+$6.09K	﹤0.01%	2442
2026 Q2	$184	Hold	13	–	–	﹤0.01%	3350
2026 Q1	$200	Sell	13 -60	-82%	-$1.07K	﹤0.01%	3218
2025 Q4	$1.12K	Hold	73	–	–	﹤0.01%	2603
2025 Q3	$1.82K	Sell	73 -150	-67%	-$4.39K	﹤0.01%	2459
2025 Q2	$8.42K	Buy	223 +214	+2,378%	+$6.2K	﹤0.01%	1777
2025 Q1	$163	Hold	9	–	–	﹤0.01%	3290
2024 Q4	$210	Buy	+9	New	+$207	﹤0.01%	3225

Other funds holding NRSN

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

SBI Securities's NRSN Position: Q3 2026 in Review

SBI Securities increased its NeuroSense Therapeutics (NRSN) stake by 4,823% in Q3 2026, buying an estimated $6.09K and bringing the position to 640 shares worth $2.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

SBI Securities first reported a position in NRSN in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.42K in Q2 2025. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

SBI Securities held 640 shares of NeuroSense Therapeutics worth $2.84K as of Q3 2026.
SBI Securities bought 627 NeuroSense Therapeutics shares in Q3 2026, an estimated $6.09K.
NeuroSense Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2442 holding.
SBI Securities first reported a position in NeuroSense Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's NeuroSense Therapeutics position peaked at $8.42K in Q2 2025.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.